Intellia Therapeutics NTLA leverages its proprietary technologies and expertise, including CRISPR-based gene-editing technologies, oligonucleotides and lipid nanoparticles (LNPs), to develop novel, first-in-class therapeutic candidates.
The company has been making decent progress with the advancement of its two pipeline candidates, lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) and nex-z (formerly NTLA-2001) for transthyretin (ATTR) amyloidosis.
Earlier this month, the FDA accepted and granted priority review to the biologics license application (BLA) seeking approval for lonvo-z, an in vivo CRISPR-based gene-editing therapy, for the treatment of HAE.
A final decision on the BLA from the regulatory body is expected on March 10, 2027.
HAE is a rare genetic disorder marked by recurrent, potentially life-threatening swelling caused by excess bradykinin. If approved, lonvo-z will become the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
In April 2026, Intellia reported positive top-line results from the global phase III HAELO study evaluating lonvo-z in HAE.
The company plans to commercially launch lonvo-z in the first half of 2027, upon potential approval in the United States. If approved and successfully commercialized, lonvo-z could significantly strengthen Intellia’s growth prospects by providing its first commercial product and a potential new revenue stream.
Besides lonvo-z, Intellia’s other pipeline candidate, nex-z, a CRISPR-based gene-edited therapy, is being developed in collaboration with Regeneron Pharmaceuticals REGN.
While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. The company’s top line currently comprises only collaboration revenues from its partners, like Regeneron and others.
Nex-z is being evaluated in two late-stage studies, MAGNITUDE and MAGNITUDE-2, for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTR amyloidosis with polyneuropathy (ATTRv-PN), respectively. If the data from the studies are found to be positive, it should likely enable global regulatory filings for nex-z. The successful development of nex-z could provide impetus to the stock and create long-term growth visibility.
However, any regulatory or developmental setback related to ongoing studies will be a major setback for Intellia. Growing competition in the target market also remains a worry.
NTLA's Competition in the Target Market
Intellia’s pipeline candidates are likely to face competition from other companies that are leveraging CRISPR/Cas9 gene-editing technology to target diseases across similar therapeutic areas.
CRISPR Therapeutics CRSP is the first company in the world to market a CRISPR/Cas9-based therapy. CRSP’s one-shot gene therapy, Casgevy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease and transfusion-dependent beta-thalassemia.
CRSP has developed Casgevy in partnership with large biotech, Vertex Pharmaceuticals, which is responsible for the therapy’s global development and commercialization.
Beam Therapeutics BEAM is developing its leading ex-vivo genome-editing candidate, risto-cel (formerly BEAM-101), in the phase I/II BEACON study for the treatment of patients with SCD. BEAM plans to submit a BLA for risto-cel by the end of 2026.
Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a and alpha-1 antitrypsin deficiency, respectively.
NTLA's Price Performance, Valuation and Estimates
Year to date, shares of Intellia have rallied 36.4% compared with the industry’s increase of 6.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intellia is trading at a discount to the industry. Going by the price/book ratio, the company’s shares currently trade at 2.35, lower than 3.87 for the industry. The stock is trading below its five-year mean of 2.50.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intellia’s 2026 loss per share has widened from $3.18 to $3.21 over the past 60 days. Meanwhile, loss per share estimates for 2027 have widened from 68 cents to $2.32 during the same time frame.
Image Source: Zacks Investment Research
NTLA's Zacks Rank
Intellia currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intellia Therapeutics, Inc. (NTLA): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Beam Therapeutics Inc. (BEAM): Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).